

## CLAIMS

1. An injection device comprising a unit dose, wherein the unit dose comprises 120 mg to 135 mg of a type I IFN receptor (IFNAR1) inhibitor, wherein the IFNAR1 inhibitor is anifrolumab and wherein the unit dose is for subcutaneous injection to a subject once a week (QW).
2. The injection device of claim 1, wherein the unit dose comprises 120 mg of the IFNAR1 inhibitor.
3. The injection device of claim 1 or 2, wherein the injection device is a prefilled syringe or an autoinjector.
4. The injection device of any of claims 1 to 3 for use in a method of treating disease in a subject, wherein the use comprises subcutaneous administration of the unit dose to the subject, wherein the disease is a type I interferon (IFN)-mediated disease.
5. The injection device for the use of claim 4, wherein the disease is an autoimmune disease.
6. The injection device for the use of claim 5, wherein the disease is lupus.
7. The injection device for the use of claim 6, wherein the disease is systemic lupus erythematosus (SLE).
8. The injection device for the use of claim 7, wherein the disease is moderate to severe, active autoantibody-positive SLE.
9. The injection device for the use of claim 6, wherein the disease is lupus nephritis (LN).
10. The injection device for the use of claim 6, wherein the disease is cutaneous lupus erythematosus (CLE).
11. The injection device for the use of claim 5, wherein the disease is myositis.
12. The injection device for the use of claim 5, wherein the disease is scleroderma.
13. The injection device of any of claims 1 to 3 for use in therapy.
14. Use of the injection device of any of claims 1-3 in the manufacture of a medicament for treating disease in a subject, wherein the unit dose is to be administered subcutaneously to the subject, wherein the disease is a type I interferon (IFN)-mediated disease.
15. The use of the injection device of claim 14, wherein the disease is an autoimmune disease.
16. The use of the injection device of claim 15, wherein the disease is lupus.
17. The use of the injection device of claim 16, wherein the disease is systemic lupus erythematosus (SLE).

18. The use of the injection device of claim 17, wherein the disease is moderate to severe, active autoantibody-positive SLE.
19. The use of the injection device of claim 16, wherein the disease is lupus nephritis (LN).
20. The use of the injection device of claim 16, wherein the disease is cutaneous lupus erythematosus (CLE).
21. The use of the injection device of claim 15, wherein the disease is myositis.
22. The use of the injection device of claim 15, wherein the disease is scleroderma.